Bromocriptine use is associated with decreased smoking rates
Murphy MF, Hey K, Johnstone E, Munafo M,
Walton R, Willis B, Harrison PJ.
University of Oxford,
ICRF General Practice Research Group,
Institute of Health Sciences, Oxford, UK.
Addict Biol 2002 Jul;7(3):325-8
Dopaminergic transmission in the central nervous system is thought to underlie addictive behaviours, including smoking. One effective smoking cessation drug, bupropion, enhances dopaminergic transmission; conversely, antipsychotic drugs, which are dopamine antagonists, are associated with increased smoking. Thus we hypothesized that subfertile women treated with the potent dopamine agonist bromocriptine might smoke less as a consequence of their treatment. Among 4608 subfertile women those conceiving on bromocriptine were half as likely to smoke as those taking other drugs or those conceiving without medication (p < 0.0001). This observation supports the role of dopamine in nicotine addiction, and suggests that bromocriptine-like drugs could be used effectively by pregnant women to aid cessation.
Bromocriptine v lisuride
Bromocriptine in psychiatry
Bromocriptine and depression
Dopaminergics and depression
Dopamine agonists for Parkinson's disease
Dopamine and dopaminergic antidepressants